Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer

Biochemical and Biophysical Research Communications

Volumn 443, Issue 1, 2014, Pages 156-160

  Yang, Bing ^a   Fu, Xueqiong ^a   Shao, Liang ^b   Ding, Yu ^a   Zeng, Duan ^a  

^a Affiliated to Guangzhou University of Traditional Chinese Medicine   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Gastric cancer; HIF 1 ; Knockdown; SIRT3; Tumor suppressor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; SIRTUIN 3;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL RATE; TUMOR DIFFERENTIATION;

GASTRIC CANCER; GC; HIF-1Α; HYPOXIA INDUCIBLE FACTOR-1Α; KNOCKDOWN; SIRT3; SIRTUIN 3; TUMOR SUPPRESSOR;

ADULT; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SIRTUIN 3; STOMACH NEOPLASMS;

EID: 84890858374     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.068     Document Type: Article

References (22)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Ali Z., Deng Y., Tang Y., Zheng S., Ma N., He N. Epigenetic deregulations in gastric cancer. J. Nanosci. Nanotechnol. 2013, 13:40-51.
3. Houtkooper R.H., Pirinen E., Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 2012, 13:225-238.
4. Bonda D.J., Lee H.G., Camins A., Pallàs M., Casadesus G., Smith M.A., Zhu X. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol. 2011, 10:275-279.
5. Borradaile N.M., Pickering J.G. NAD(+), sirtuins, and cardiovascular disease. Curr. Pharm. Des. 2009, 15:110-117.
6. Hall J.A., Dominy J.E., Lee Y., Puigserver P. The sirtuin family's role in aging and age-associated pathologies. J. Clin. Invest. 2013, 123:973-979.
7. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587-591.
8. Baur J.A., Ungvari Z., Minor R.K., Le Couteur D.G., de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan?. Nat. Rev. Drug. Discov. 2012, 11:443-461.
9. Giralt A., Villarroya F. SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging. Biochem. J. 2012, 444:1-10.
10. Zhang C.Z., Liu L., Cai M., Pan Y., Fu J., Cao Y., Yun J. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS ONE 2012, 7:e51703.
11. Zhang Y.Y., Zhou L.M. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem. Biophys. Res. Commun. 2012, 423:26-31.
12. Finley L.W., Carracedo A., Lee J., Souza A., Egia A., Zhang J., Teruya-Feldstein J., Moreira P.I., Cardoso S.M., Clish C.B., Pandolfi P.P., Haigis M.C. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 2011, 19:416-428.
13. Xiao K., Jiang J., Wang W., Cao S., Zhu L., Zeng H., Ouyang R., Zhou R., Chen P. Sirt3 is a tumor suppressor in lung adenocarcinoma cells. Oncol. Rep. 2013, 30:1323-1328.
14. Lai C.C., Lin P.M., Lin S.F., Hsu C.H., Lin H.C., Hu M.L., Hsu C.M., Yang M.Y. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 2013, 34:1847-1854.
15. Kim H.S., Patel K., Muldoon-Jacobs K., Bisht K.S., Aykin-Burns N., Pennington J.D., van der Meer R., Nguyen P., Savage J., Owens K.M., Vassilopoulos A., Ozden O., Park S.H., Singh K.K., Abdulkadir S.A., Spitz D.R., Deng C.X., Gius D. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
16. Schumacker P.T. SIRT3 controls cancer metabolic reprogramming by regulating ROS and HIF. Cancer Cell 2011, 19:299-300.
17. Alhazzazi T.Y., Kamarajan P., Verdin E., Kapila Y.L. SIRT3 and cancer: tumor promoter or suppressor?. Biochim. Biophys. Acta 1816, 2011:80-88.
18. Finley L.W., Haigis M.C. Metabolic regulation by SIRT3: implications for tumorigenesis. Trends Mol. Med. 2012, 18:516-523.
19. Alhazzazi T.Y., Kamarajan P., Joo N., Huang J.Y., Verdin E., D'Silva N.J., Kapila Y.L. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011, 117:1670-1678.
20. Haigis M.C., Deng C.X., Finley L.W., Kim H.S., Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2012, 72:2468-2472.
21. Bell E.L., Emerling B.M., Ricoult S.J., Guarente L. SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011, 30:2986-2996.
22. Greer S.N., Metcalf J.L., Wang Y., Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012, 31:2448-2460.